Skip to main content

Advertisement

SpringerLink
Log in

Association between antidepressant use and second breast cancer event after ductal carcinoma in situ diagnosis: a nested case–control study

  • Original Paper
  • Published:
Cancer Causes & Control Aims and scope Submit manuscript

Abstract

Purpose

Controversy exists regarding the potential relationship between antidepressant use and risk of breast cancer. No previous studies have evaluated the relationship between antidepressant use after diagnosis of ductal carcinoma in situ (DCIS) and risk of a subsequent breast cancer restricted to women with a history of DCIS.

Methods

We conducted a population-based, nested case–control study in western Washington State. Cases included 337 women diagnosed with DCIS and a subsequent breast cancer and they were compared to 592 individually matched controls (on age, year of DCIS diagnosis, primary treatment, histology, grade, and disease-free survival time) who were diagnosed with DCIS but not a subsequent breast cancer. Information on antidepressant use after DCIS diagnosis was obtained from comprehensive medical records reviews. Antidepressant use was defined as greater or equal to 3 months of duration.

Results

Antidepressant use after initial DCIS was associated with a 1.4-fold increased risk of a subsequent breast cancer event (adjusted OR 1.41, 95% CI 1.02, 1.95). Similar risks were observed when assessing individual antidepressant classes, however, there was no sufficient power across specific classes of antidepressants.

Conclusions

Antidepressant use after DCIS diagnosis was associated with an increased risk of subsequent breast cancer in women. Further studies are needed to confirm the associations observed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Data availability

The datasets used during the study are available from the corresponding author on reasonable request.

Code availability

The software code used during the study are available from the corresponding author on reasonable request.

References

  1. American Cancer Society (2019) Breast Cancer Facts & Figures 2019–2020. American Cancer Society, Inc. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/breast-cancer-facts-and-figures/breast-cancer-facts-and-figures-2019-2020.pdf. Accessed May 2, 2021

  2. Habel LA, Daling JR, Newcomb PA et al (1998) Risk of recurrence after ductal carcinoma in situ of the breast. Cancer Epidemiol Biomark Prev 7(8):689–696

    CAS  Google Scholar 

  3. McLaughlin VH, Trentham-Dietz A, Hampton JM, Newcomb PA, Sprague BL (2014) Lifestyle factors and the risk of a second breast cancer after ductal carcinoma in situ. Cancer Epidemiol Biomark Prev 23(3):450–460. https://doi.org/10.1158/1055-9965.EPI-13-0899

    Article  Google Scholar 

  4. Flanagan MR, Tang M-TC, Baglia ML, Porter PL, Malone KE, Li CI (2018) Relationship between anthropometric factors and risk of second breast cancer among women with a history of ductal carcinoma in situ. JNCI Cancer Spectr 2(2):pky020. https://doi.org/10.1093/jncics/pky020

    Article  PubMed  PubMed Central  Google Scholar 

  5. Brown SB, Hankinson SE, Arcaro KF, Qian J, Reeves KW (2016) Depression, antidepressant use, and postmenopausal breast cancer risk. Cancer Epidemiol Biomark Prev 25(1):158–164. https://doi.org/10.1158/1055-9965.EPI-15-1063

    Article  CAS  Google Scholar 

  6. Reeves KW, Okereke OI, Qian J, Tamimi RM, Eliassen AH, Hankinson SE (2018) Depression, antidepressant use, and breast cancer risk in pre- and postmenopausal women: a prospective cohort study. Cancer Epidemiol Biomark Prev 27(3):306–314. https://doi.org/10.1158/1055-9965.EPI-17-0707

    Article  Google Scholar 

  7. Harvey PW, Everett DJ, Springall CJ (2008) Adverse effects of prolactin in rodents and humans: breast and prostate cancer. J Psychopharmacol 22(2_suppl):20–27. https://doi.org/10.1177/0269881107082624

    Article  PubMed  Google Scholar 

  8. Kelly CM, Juurlink DN, Gomes T et al (2010) Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. BMJ 340:c693. https://doi.org/10.1136/bmj.c693

    Article  PubMed  PubMed Central  Google Scholar 

  9. Busby J, Mills K, Zhang S-D, Liberante FG, Cardwell CR (2018) Selective serotonin reuptake inhibitor use and breast cancer survival: a population-based cohort study. Breast Cancer Res 20(1):4. https://doi.org/10.1186/s13058-017-0928-0

    Article  PubMed  PubMed Central  Google Scholar 

  10. Steingart A, Cotterchio M, Kreiger N, Sloan M (2003) Antidepressant medication use and breast cancer risk: a case-control study. Int J Epidemiol 32(6):961–966. https://doi.org/10.1093/ije/dyg155

    Article  PubMed  Google Scholar 

  11. Moorman PG, Grubber JM, Millikan RC, Newman B (2003) Antidepressant medications and their association with invasive breast cancer and carcinoma in situ of the breast. Epidemiology 14(3):307–314

    PubMed  Google Scholar 

  12. Fulton-Kehoe D, Rossing MA, Rutter C, Mandelson MT, Weiss NS (2006) Use of antidepressant medications in relation to the incidence of breast cancer. Br J Cancer 94(7):1071–1078. https://doi.org/10.1038/sj.bjc.6603017

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Wernli KJ, Hampton JM, Trentham-Dietz A, Newcomb PA (2009) Antidepressant medication use and breast cancer risk. Pharmacoepidemiol Drug Saf 18(4):284–290. https://doi.org/10.1002/pds.1719

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Chubak J, Buist DSM, Boudreau DM, Rossing MA, Lumley T, Weiss NS (2008) Breast cancer recurrence risk in relation to antidepressant use after diagnosis. Breast Cancer Res Treat 112(1):123–132. https://doi.org/10.1007/s10549-007-9828-9

    Article  CAS  PubMed  Google Scholar 

  15. Haque R, Shi J, Schottinger JE et al (2015) Tamoxifen and antidepressant drug interaction among a cohort of 16 887 breast cancer survivors. J Natl Cancer Inst. https://doi.org/10.1093/jnci/djv337

    Article  PubMed  PubMed Central  Google Scholar 

  16. Chubak J, Bowles EJA, Yu O, Buist DSM, Fujii M, Boudreau DM (2016) Breast cancer recurrence in relation to antidepressant use. Cancer Causes Control 27(1):125–136. https://doi.org/10.1007/s10552-015-0689-y

    Article  PubMed  Google Scholar 

  17. Valachis A, Garmo H, Weinman J et al (2016) Effect of selective serotonin reuptake inhibitors use on endocrine therapy adherence and breast cancer mortality: a population-based study. Breast Cancer Res Treat 159(2):293–303. https://doi.org/10.1007/s10549-016-3928-3

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Li R, Li X, Yan P et al (2021) Relationship between antidepressive agents and incidence risk of breast cancer: systematic review and meta-analysis. Future Oncol 17(9):1105–1124. https://doi.org/10.2217/fon-2020-0822

    Article  CAS  PubMed  Google Scholar 

  19. Baglia ML, Tang M-TC, Malone KE, Porter P, Li CI (2018) Family history and risk of second primary breast cancer after in situ breast carcinoma. Cancer Epidemiol Biomark Prev 27(3):315–320. https://doi.org/10.1158/1055-9965.EPI-17-0837

    Article  Google Scholar 

  20. Baglia ML, Tang M-TC, Malone KE, Porter P, Li CI (2019) Reproductive and menopausal factors and risk of second primary breast cancer after in situ breast carcinoma. Cancer Causes Control 30(1):113–120. https://doi.org/10.1007/s10552-018-1119-8

    Article  PubMed  Google Scholar 

  21. Li CI, Flanagan MR, Tang M-TC, Porter PL, Malone KE (2021) Bisphosphonate use and breast cancer risk among women with ductal carcinoma in situ. Cancer Res 81(10):2799–2802. https://doi.org/10.1158/0008-5472.CAN-20-4100

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. DeCensi A, Puntoni M, Guerrieri-Gonzaga A et al (2019) Randomized placebo controlled trial of low-dose tamoxifen to prevent local and contralateral recurrence in breast intraepithelial neoplasia. J Clin Oncol 37(19):1629–1637. https://doi.org/10.1200/JCO.18.01779

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Early Breast Cancer Trialists’ Collaborative Group (2011) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378(9793):771–784. https://doi.org/10.1016/S0140-6736(11)60993-8

    Article  CAS  Google Scholar 

  24. Chien C, Li CI, Heckbert SR, Malone KE, Boudreau DM, Daling JR (2006) Antidepressant use and breast cancer risk. Breast Cancer Res Treat 95(2):131–140. https://doi.org/10.1007/s10549-005-9056-0

    Article  PubMed  Google Scholar 

  25. Cronin-Fenton DP, Lash TL (2011) Clinical epidemiology and pharmacology of CYP2D6 inhibition related to breast cancer outcomes. Expert Rev Clin Pharmacol 4(3):363–377. https://doi.org/10.1586/ecp.11.18

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Donneyong MM, Bykov K, Bosco-Levy P, Dong Y-H, Levin R, Gagne JJ (2016) Risk of mortality with concomitant use of tamoxifen and selective serotonin reuptake inhibitors: multi-database cohort study. BMJ 354:i5014. https://doi.org/10.1136/bmj.i5014

    Article  PubMed  PubMed Central  Google Scholar 

  27. Lash TL, Cronin-Fenton D, Ahern TP et al (2010) Breast cancer recurrence risk related to concurrent use of SSRI antidepressants and tamoxifen. Acta Oncol 49(3):305–312. https://doi.org/10.3109/02841860903575273

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Dusetzina SB, Alexander GC, Freedman RA, Huskamp HA, Keating NL (2013) Trends in co-prescribing of antidepressants and tamoxifen among women with breast cancer, 2004–2010. Breast Cancer Res Treat 137(1):285–296. https://doi.org/10.1007/s10549-012-2330-z

    Article  PubMed  Google Scholar 

  29. Soltamox (tamoxifen citrate) Drug Label (2018). FDA. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021807s005lbl.pdf. Accessed May 2, 2021

  30. Wedret JJ, Tu TG, Paul D, Rousseau C, Bonta A, Bota RG (2019) Interactions between antidepressants, sleep aids and selected breast cancer therapy. Ment Illn. https://doi.org/10.4081/mi.2019.8115

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Funding

This study was funded by the National Cancer Institute (R01-CA097271).

Author information

Authors and Affiliations

  1. School of Public Health, University of Washington, Seattle, USA

    Elizabeth T. Mansi, Kathleen E. Malone, Nicole C. Loroña & Christopher I. Li

  2. Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave. N., M4-C308, Seattle, WA, 98109, USA

    Elizabeth T. Mansi, Kathleen E. Malone, Mei-Tzu Tang, Nicole C. Loroña & Christopher I. Li

Authors
  1. Elizabeth T. Mansi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kathleen E. Malone
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mei-Tzu Tang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Nicole C. Loroña
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Christopher I. Li
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christopher I. Li.

Ethics declarations

Conflict of interest

The authors declare no potential conflicts of interest.

Ethical approval

The study was approved by the Institutional Review Board at the Fred Hutchinson Cancer Research Center.

Consent to participate

Informed consent was obtained from all individual participants included in the study.

Consent for publication

Not applicable.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mansi, E.T., Malone, K.E., Tang, MT. et al. Association between antidepressant use and second breast cancer event after ductal carcinoma in situ diagnosis: a nested case–control study. Cancer Causes Control 33, 593–600 (2022). https://doi.org/10.1007/s10552-021-01551-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10552-021-01551-w

Keywords

Search

Navigation